Share
Services
If no timeframe is specified, information refers to fiscal year 2015.
Fiscal year 2015:
Q4/2015:
Group guidance 2016:
Targets 20193:
Ulf Mark Schneider, CEO of Fresenius, said: "2015 was a remarkable year for Fresenius with double-digit sales and earnings growth. Patient focus and an uncompromising commitment to product and service quality are key to our success. Our growth story continues. We see significant opportunities around the globe for the company’s strong and balanced healthcare portfolio, and this confidence is reflected in our new 2019 Group targets."
1 2015 before special items but including GranuFlo®/NaturaLyte® settlement costs ( €54 million before tax; €10 million after tax)2 Net income attributable to shareholders of Fresenius SE & Co. KGaA3 At comparable exchange rates; includes small and mid-size acquisitions
Positive Group guidance for 2016
For 2016, Fresenius projects sales growth of 6% to 8% in constant currency. Net income1 is expected to grow by 8% to 12% in constant currency.
The net debt/EBITDA2 ratio is expected to be approximately 2.5 at the end of 2016.
New stretch targets for 20193
For 2019, Group sales are expected to reach €36 billion to €40 billion. Group net income4 is expected to increase to €2.0 billion to €2.25 billion.
1 Net income attributable to shareholders of Fresenius SE & Co. KGaA; 2015 before special items but including GranuFlo®/NaturaLyte® settlement costs2 Calculated at expected annual average exchange rates, for both net debt and EBITDA; without large unannounced acquisitions3 At comparable exchange rates; including small and mid-size acquisitions4 Net income attributable to shareholders of Fresenius SE & Co. KGaA
23rd consecutive dividend increase proposed
Based on the strong financial results, the Management Board will propose to the Supervisory Board a dividend increase of 25% to €0.55 per share (2014: €0.44). The total dividend distribution is expected to be €300 million.
9% sales growth in constant currency – fully in line with guidance
Group sales increased by 19% (9% in constant currency) to €27,626 million (2014: €23,231 million). Organic sales growth was 6%. Acquisitions contributed 4% and divestitures reduced sales by 1%. Positive currency translation effects (10%) were mainly driven by the Euro’s depreciation against the U.S. dollar. In Q4/2015, Group sales increased by 11% (5% in constant currency) to €7,257 million (Q4/2014: €6,520 million). Organic sales growth was 5%. Acquisitions contributed 1%, while divestitures reduced sales by 1%.
Group sales by region:
21% net income1,2 growth in constant currency – fully in line with guidance
Group EBITDA2 increased by 24% (12% in constant currency) to €5,073 million (2014: €4,095 million). Group EBIT2 increased by 25% (13% in constant currency) to €3,958 million (2014: €3,158 million). The EBIT margin2 increased to 14.3% (2014: 13.6%).
In Q4/2015, Group EBIT2 increased by 19% (10% in constant currency) to €1,109 million (Q4/2014: €935 million), the EBIT margin2 improved to 15.3% (Q4/2014: 14.3%).
Group net interest increased slightly to -€613 million (2014: -€602 million). More favourable financing terms and interest rate savings on lower debt were more than offset by currency translation effects. In Q4/2015, Group net interest of -€137 million was below the prior-year level (Q4/2014: -€171 million). Lower negative currency translation effects in Q4/2015 were more than offset by interest savings on lower debt.
The Group tax rate2 increased to 29.4% (2014: 28.4%), mainly due to the higher U.S. share of earnings before tax.
Noncontrolling interest was €939 million (2014: €745 million), of which 95% was attributable to the noncontrolling interest in Fresenius Medical Care.
Group net income1,2 increased by 31% (21% in constant currency) to €1,423 million (2014: €1,086 million). Earnings per share1,2 increased by 30% (20% in constant currency) to €2.61 (2014: €2.01). In Q4/2015, Group net income1,2 increased by 30% (24% in constant currency) to €414 million (Q4/2014: €318 million). Earnings per share1,2 increased by 27% (22% in constant currency) to €0.75 (Q4/2014: €0.59).
Group net income1 including special items increased by 27% (17% in constant currency) to €1,358 million (2014: €1,067 million). Earnings per share1 including special items increased by 27% (16% in constant currency) to €2.50 (2014: € 1.97). In Q4/2015, Group net income1 including special items increased by 40% (32% in constant currency) to €359 million (Q4/2014: €257 million). Earnings per share1 including special items increased by 40% (32% in constant currency) to €0.66 (Q4/2014: €0.47).
1 Net income attributable to shareholders of Fresenius SE & Co. KGaA2 Before special items but including GranuFlo®/NaturaLyte® settlement costs ( €54 million before tax; €10 million after tax)
Continued investment in growth
Spending on property, plant and equipment was €1,512 million (2014: €1,345 million), primarily for the modernization and expansion of dialysis clinics, production facilities and hospitals. This corresponds to 5.5% of sales.
Total acquisition spending was €517 million (2014: €2,450 million).
Excellent cash flow development
Operating cash flow increased by 29% to €3,327 million (2014: €2,585 million) with a margin of 12.0% (2014: 11.1%). The Euro’s depreciation against the U.S. dollar positively influenced 2015 operating cash flow, while 2014 operating cash flow was reduced by the US$1151 million payment for the W.R. Grace bankruptcy settlement. The excellent cash flow margin demonstrates the underlying strength of cash flow generation across all business segments. Operating cash flow in Q4/2015 increased by 32% to €1,176 million (Q4/2014: €890 million) with a margin of 16.2% (Q4/2014: 13.7%).
Free cash flow before acquisitions and dividends increased by 48% to €1,865 million (2014: €1,262 million), with a margin of 6.8% (2014: 5.4%). Free cash flow after acquisitions and dividends improved to €1,194 million (2014: €1,348 million).
1 See Annual Report 2014, page 152 f.
Solid balance sheet structure1
The Group’s total assets increased by 9% (3% in constant currency) to €43,170 million (Dec. 31, 2014: €39,788 million). This increase is mainly attributable to currency translation effects. Current assets grew by 9% (6% in constant currency) to €10,917 million (Dec. 31, 2014: €10,012 million). Non-current assets increased by 8% (2% in constant currency) to €32,253 million (Dec. 31, 2014: € 29,776 million).
Total shareholders’ equity increased by 16% (11% in constant currency) to €18,003 million (Dec. 31, 2014: €15,483 million). The equity ratio increased to 41.7% (Dec. 31, 2014: 38.9%).
Group debt decreased by 4% (-9% in constant currency) to €14,769 million (Dec. 31, 2014: € 15,345 million). As of December 31, 2015, the net debt/EBITDA ratio was 2.682. As of December 31, 2014, the ratio was 3.243. EBITDA growth as well as the net debt reduction by application of meaningful free cash flow have equally contributed to this substantial decrease of the ratio.
1 2014 adjusted due to debt issuance cost restatement (U.S. GAAP standard ASU 2015-03)2 Before special items; at LTM average exchange rates for both net debt and EBITDA3 Pro forma acquisitions; before special items; at LTM average exchange rates for both net debt and EBITDA
Business Segments
Fresenius Medical Care
Fresenius Medical Care is the world's largest provider of products and services for individuals with renal diseases. As of December 31, 2015, Fresenius Medical Care was treating 294,381 patients in 3,418 dialysis clinics. Along with its core business, the company seeks to expand the range of medical services in the field of care coordination.
Sales increased by 6% (11% in constant currency) to US$16,738 million (2014: US$15,832 million). Organic sales growth was 6%. Acquisitions contributed 6%, while divestitures reduced sales by 1%. Currency translation effects reduced sales by 5%. In Q4/2015, sales increased by 1% (5% in constant currency) to US$4,348 million (Q4/2014: US$4,320 million).
Health Care services sales (dialysis services and care coordination) increased by 9% (13% in constant currency) to US$13,392 million (2014: US$12,250 million). Dialysis product sales decreased by 7% (increased by 4% in constant currency) to US$3,346 million (2014: US$3,582 million).
In North America, sales increased by 13% to US$11,813 million (2014: US$10,500 million). Health Care services sales grew by 13% to US$10,932 million (2014: US$9,655 million). Dialysis product sales increased by 4% to US$881 million (2014: US$845 million).
Sales outside North America decreased by 7% (increased by 9% in constant currency) to US$4,897 million (2014: US$5,265 million). Health Care services sales decreased by 5% (increased by 12% in constant currency) to US$2,459 million (2014: US$2,595 million).
Dialysis product sales decreased by 9% (increased by 6% in constant currency) to US$2,437 million (2014: US$2,670 million).
EBIT increased by 3% (8% in constant currency) to US$2,327 million (2014: US$2,255 million). The EBIT margin was 13.9% (2014: 14.2%). Based on the agreement in principle to resolve the GranuFlo®/NaturaLyte® product liability litigation, Fresenius Medical Care expects a pre-tax financial impact of US$60 million from the settlement. Adjusted for one-time items4, EBIT increased by 5% to US$2,388 million. In Q4/2015, EBIT remained roughly flat at US$662 million (Q4/2014: US$663 million). In constant currency, EBIT increased by 3%. The EBIT margin was 15.2% (Q4/2014: 15.4%). EBIT excluding one-time items5 increased by 5% to US$704 million.
Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA excluding one-time items4 increased by 2% to US$1,082 million. Net income including one-time items decreased by 2% (increased by 3% in constant currency) to US$1,029 million (2014: US$1,045 million). Net income attributable to non-controlling interest increased by 32% to US$284 million, mainly due to the strong earnings development in North America. In Q4/2015, net income excluding one-time items5 increased by 2% to US$347 million. Net income including one-time items decreased by 6% (-3% in constant currency) to US$317 million (Q4/2014: US$335 million).
Operating cash flow increased by 5% to US$1,960 million (2014: US$1,861 million). Operating cash flow in the prior-year period was reduced by the US$115 million6 payment for the W.R. Grace bankruptcy settlement. The cash flow margin was 11.7% (2014: 11.8%). In Q4/2015, operating cash flow reached an excellent US$548 million (Q4/2014: US$588 million) at a margin of 12.6% (Q4/2014: 13.6%).
Fresenius Medical Care confirms its outlook for 2016. The company expects sales to grow by 7% to 10% in constant currency and net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA is expected to increase by 15% to 20%3 in 2016.
The outlook is based on current exchange rates. Savings from the global efficiency program are included, while earnings contributions from acquisitions 2015/2016 are not.
For further information, please see Fresenius Medical Care’s Press Release at
www.freseniusmedicalcare.com.
1 Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA2 2015 before GranuFlo®/NaturaLyte® settlement costs (-US$37 million after tax), before divestiture of dialysis business in Venezuela (-US$27 million after tax) and European pharmaceutical business (US$11 million after tax); 2014 before closing of manufacturing plant (-US$13 million after tax)3 2015 before GranuFlo®/NaturaLyte® settlement costs (-US$37 million after tax) and before acquisitions (US$9 million after tax); hence the basis for expected net income growth are US$1,057 million.4 2015 before GranuFlo®/NaturaLyte® settlement costs (-US$60 million before tax; -US$37 million after tax), before divestiture of dialysis business in Venezuela (-US$26 million before tax; -US$27 million after tax) and European pharmaceutical business (US$25 million before tax; US$11 million after tax); 2014 before closing of manufacturing plant (-US$16 million before tax; -US$13 million after tax)5 Q4/2015 before GranuFlo®/NaturaLyte® settlement costs (-US$60 million before tax; -US$37 million after tax), before divestiture of European pharmaceutical business (US$18 million before tax; US$7 million after tax); 2014 before closing of manufacturing plant (-US$6 million before tax; -US$6 million after tax)6 See Annual Report 2014, page 152 f.
Fresenius Kabi
Fresenius Kabi offers intravenously administered generic drugs, clinical nutrition and infusion therapies for seriously and chronically ill patients in the hospital and outpatient environments. The company is also a leading supplier of medical devices and transfusion technology products.
Sales increased by 16% (7% in constant currency) to €5,950 million (2014: €5,146 million). Organic sales growth was 8%. Acquisitions contributed 1% while divestitures reduced sales by 2%. Positive currency translation effects (9%) were mainly driven by the Euro’s depreciation against the U.S. dollar and the Chinese yuan. In Q4/2015, sales increased by 10% (5% in constant currency) to €1,519 million (Q4/2014: €1,386 million). Organic sales growth was 8%.
Sales in Europe grew by 1% (organic growth: 4%) to €2,123 million (2014: €2,102 million). Sales in North America increased by 37% (organic growth: 16%) to €2,093 million (2014: €1,531 million). North American sales growth was driven by persisting IV drug shortages and new product launches. Asia-Pacific sales increased by 16% (organic growth: 5%) to €1,141 million (2014: €987 million). Sales in Latin America/Africa grew by 13% (organic growth: 13%) to €593 million (2014: €526 million).
EBIT1 increased by 36% (21% in constant currency) to €1,189 million (2014: €873 million). The EBIT margin1 improved to 20.0% (2014: 17.0%). In Q4/2015, EBIT1 increased by 33% (26% in constant currency) to €317 million (Q4/2014: €239 million). The EBIT margin1 increased to 20.9% (Q4/2014: 17.2%). The EBIT margin was positively influenced by the Euro’s depreciation against the U.S. dollar.
Net income2 increased by 43% (27% in constant currency) to €669 million (2014: €468 million). In Q4/2015, net income2 increased by 45% (38% in constant currency) to €190 million (Q4/2014: €131 million).
Operating cash flow increased by 42% to €913 million (2014: €641 million) with a margin of 15.3% (2014: 12.5%). In Q4/2015, operating cash flow increased by 55% to €324 million (Q4/2014: €209 million) with a margin of 21.3% (Q4/2014: 15.1%).
Fresenius Kabi’s initiatives to increase production efficiency and streamline administrative structures are well on track. Costs of €105 million before tax were incurred in 2015. These costs are reported in the Group segment Corporate/Other. The program led to initial cost savings of approximately €10 million in 2015. The targeted savings run-rate of approximately €40 million p.a. is expected by 2018.
For 2016, Fresenius Kabi expects to achieve low single-digit organic sales growth. EBIT3 in constant currency is expected to be roughly flat.
1 Before special items2 Net income attributable to shareholders of Fresenius Kabi AG; before special items3 2015 before special items
Fresenius Helios
Fresenius Helios is Germany’s largest hospital operator. HELIOS operates 111 hospitals, thereof 87 acute care clinics (including seven maximum care hospitals in Berlin-Buch, Duisburg, Erfurt, Krefeld, Schwerin, Wiesbaden and Wuppertal) and 24 post-acute care clinics. HELIOS treats more than 4.7 million patients per year, thereof approximately 1.3 million inpatients, and operates more than 34,000 beds.
Sales increased by 6% to €5,578 million (2014: €5,244 million). Organic sales growth was 3%. Acquisitions contributed 4%, while divestitures reduced sales by 1%. In Q4/2015, sales increased by 4% to €1,411 million (Q4/2014: €1,361 million), organic sales growth was 4%.
EBIT1 grew by 16% to €640 million (2014: €553 million). The EBIT margin1 increased to 11.5% (2014: 10.5%). The increase is attributable both to the successful integration of the acquired hospitals from Rhön-Klinikum AG and to continuous improvements of the established business. In Q4/2015, EBIT1 increased by 8% to €168 million (Q4/2014: €156 million) with a margin1 of 11.9% (Q4/2014: 11.5%).
Net income2 increased by 21% to €483 million (2014: €400 million). In Q4/2015, net income2 increased by 15% to €131 million (Q4/2014: €114 million).
Sales of the established hospitals grew by 3% to €5,379 million (2014: €5,222 million). EBIT1 increased by 15% to €631 million (2014: €551 million). The EBIT margin1 increased to 11.7% (2014: 10.6%). Sales of the newly acquired hospitals (consolidation ≤1 year) were €199 million. EBIT1 was €9 million with a margin of 4.5%.
The integration of the hospitals acquired from Rhön-Klinikum AG remains well on track. Integration costs in 2015 were €12 million (Q4/2015: €0 million) taking the total to date to €63 million. Fresenius Helios does not expect any further integration costs. Amount (€85 million p.a.) and timing (spring 2016) of targeted near-term cost synergies are confirmed.
For 2016, Fresenius Helios projects organic sales growth of 3% to 5%. EBIT is expected to increase to €670 to €700 million.
1 Before special items2 Net income attributable to shareholders of HELIOS Kliniken GmbH; before special items
Fresenius Vamed
Fresenius Vamed manages projects and provides services for hospitals and other health care facilities worldwide. The portfolio ranges along the entire value chain: from project development, planning, and turnkey construction, via maintenance and technical management, to total operational management.
Sales increased by 7% (6% in constant currency) to €1,118 million (2014: €1,042 million). Organic sales growth was 6%. Sales in the project business increased by 3% to €575 million (2014: €558 million). Sales in the service business grew by 12% to €543 million (2014: €484 million). In Q4/2015, sales remained unchanged at €387 million compared to the prior-year. Organic sales growth was 1%.
EBIT grew by 8% to €64 million (2014: €59 million). The EBIT margin remained unchanged at 5.7%. In Q4/2015, EBIT increased by 6% to €34 million (Q4/2014: €32 million). The EBIT margin increased by 50 bps to 8.8%.
Net income1 grew by 7% to €44 million (2014: €41 million). In Q4/2015, net income1 increased by 4% to €24 million (Q4/2014: €23 million).
Order intake increased to €904 million (2014: €840 million), reaching an all-time high. As of December 31, 2015, order backlog was €1,650 million (Dec. 31, 2014: €1,398 million).
For 2016, Fresenius Vamed expects organic sales growth in the range of 5% to 10% and EBIT growth of 5% to 10%.
1 Net income attributable to shareholders of VAMED AG
Press Conference
As part of the publication of the results for fiscal year 2015, a press conference will be held on February 24, 2016 at 10 a.m. CET. You are cordially invited to follow the press conference in a live broadcast over the Internet at www.fresenius.com/media. Following the press conference, a replay will be available on our website.
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.
Industrial production of infusion solutions at Fresenius Kabi's plant in Friedberg, Germany. Visual check of freeflex® bags.
Fresenius Helios acquires the municipal hospital in Velbert located in the German state of North Rhine-Westphalia. The hospital has 519 beds and, with approximately 1,000 employees, treats 45,000 patients each year, including 20,000 inpatients. Sales were approximately €67 million in 2014.
Fresenius Helios will fully own the hospital. Following the acquisition, it plans to invest in a new, state-of-the-art hospital building. The facility is an excellent fit with the company’s existing presence and activities in North Rhine-Westphalia.
The acquisition is subject to approval by the German antitrust authorities. The parties agreed not to disclose the purchase price. The transaction is expected to close in the second quarter of 2016, and the hospital will already be accretive to Fresenius Group earnings starting this year.
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.
Fresenius Helios acquires the municipal hospital in Velbert located in the German state of North Rhine-Westphalia. The hospital has 519 beds and, with approximately 1,000 employees, treats 45,000 patients each year, including 20,000 inpatients. Sales were approximately €67 million in 2014.
Fresenius Helios will fully own the hospital. Following the acquisition, it plans to invest in a new, state-of-the-art hospital building. The facility is an excellent fit with the company’s existing presence and activities in North Rhine-Westphalia.
The acquisition is subject to approval by the German antitrust authorities. The parties agreed not to disclose the purchase price. The transaction is expected to close in the second quarter of 2016, and the hospital will already be accretive to Fresenius Group earnings starting this year.
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.
Fresenius Medical Care AG & Co. KGaA (“the company” or “Fresenius Medical Care”), the world’s largest provider of dialysis products and services, today announced that Fresenius Medical Care North America (FMCNA) has reached an agreement in principle with a committee designated by the plaintiffs to resolve litigation in the United States involving GranuFlo®/NaturaLyte®.
Under the agreement in principle, the settlement amount would be $250 million, provided that 97% of all plaintiffs agree to the settlement by July 2016 with the funding provided in August 2016. Insurers will fund the settlement amount with $220 million.
Therefore, the company expects a pre-tax charge of $60 million from the settlement and other costs to finalize this matter. This impact for the company will be reflected in its 2015 numbers to be published on February 24, 2016.
For 2015 the company expects to report revenues of approximately $16.7 billion. Excluding the charge net of tax, the 2015 net income attributable to shareholders should increase by approximately 2% over the prior year period. On that basis the company expects to be in line with its financial guidance for 2015.
The company’s GranuFlo®/NaturaLyte® product at issue in the litigation remains on the market and continues to be the market leader for dialysis acid concentrates in the United States. There has been no change in the composition of the product and it remains safe and effective when used and prescribed as directed.
Fresenius Medical Care is the world's largest provider of products and services for individuals with renal diseases of which more than 2.6 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,402 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 290,250 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with the core business, the company focuses on expanding the range of additional medical services in the field of care coordination.
For more information visit the Company’s website at www.freseniusmedicalcare.com.
Disclaimer
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.
May 17, 2016
Rancho Palos Verdes, USA
May 17 - 18, 2016
Medical progress is steadily increasing life expectancy for cancer patients. A study by VAMED of some 1,000 cancer patients in Austria shows that rehabilitation is improving their quality of life. Cases of depression fell by half after oncological rehabilitation, according to the study, carried out at VAMED’s rehabilitation center in St. Veit, Austria. Anxiety about a possible recurrence of cancer fell by a similar amount. Fresenius Vamed operates 15 rehabilitation centers in Europe.
